Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

THANK YOU

 

We salute our global community of clinicians who are on the front lines of the coronavirus pandemic. Thank you for helping us all be safe and stay well.

alert
International Psoriasis Council Statement on the Coronavirus (COVID-19) Outbreak
READ MORE             
now available

COVID-19 Psoriasis Resource Center

Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve.

 Explore now

Upcoming IPC Events

september 2, 2020

ESDR | AMSTERDAM, NETHERLANDS

SEPTEMBER 12, 2020

jspr | FUKUSHIMA, JAPAN


Psoriasis News

3/31/2020 10:15:00 AM
Lilly's TALTZ® (IXEKIZUMAB) receives U.S. FDA approval for the treatment of pediatric patients with moderate to severe plaque psoriasis
3/11/2020 1:09:00 PM
For psoriasis patients diagnosed with COVID-19 disease, the IPC recommends physicians discontinue or postpone use of immunosuppressant medications. This is in accordance with established psoriasis treatment guidelines, which state immunosuppressive psoriasis treatments are contraindicated in patients with active infections.
2/6/2020 10:54:00 AM
Just published - IPC's latest issue of the Psoriasis Review newsletter is now available! This issue features the Top Five Papers in psoriasis research, symposia reports, IPC news, and more!
2/6/2020
 
More News Subscribe to News feed
IPC Psoriasis Review Newsletter

IPC's bi-annual review of the latest manuscripts  in the field of psoriasis.

Read the latest issue
We use cookies on this website to enhance your experience. By continuing with this website, you consent to our use of cookies. Learn more.
OK